Table 2.

Data summary for candidate efficacy and safety biomarkers in anti-neutrophil antibody-associated vasculitis.

Protein	Mean RFU’s Pre- treatment	Mean RFU’s Posttreatment	Mean difference Pre- to Post- treatment	Ratio (Post/ Pre)	Longitudinal paired t-test (P-value)	Wilcoxon signed rank test (P-value)
Candidate Efficacy biomarkers
MMP-12	2840	1469	−1370	0.52	< 0.0001***	< 0.0001***
CD23	6122	3639	−2483	0.59	0.0015**	< 0.0001***
MDC	1857	1416	−440	0.76	0.0002***	< 0.0001***
Protein C	1945	2194	249	1.13	0.0002***	0.0003***
IL-22BP	4025	2934	−1091	0.73	0.0017**	0.002**
LY9	4868	4134	−733	0.85	0.003**	0.003**
FGG	11,867	10,624	−1243	0.90	0.018*	0.036*
ANGPT2	197	181	−16.6	0.92	0.055	0.041*
LT a1/b2	196	177	−19.3	0.90	0.043*	0.084
IGFBP-2	614	565	−49.3	0.92	0.297	0.393
ITGA1 ITGB1	851	752	−99.3	0.88	0.236	0.761
Candidate Safety biomarkers
Afamin	31,807	36,914	5106	1.16	0.0002***	< 0.0001***
Leptin	10,154	11,280	1126	1.11	0.015*	0.012**
Angiotensinogen	7260	8737	1476	1.20	0.006**	0.002**
MMP-3	3832	7345	3512	1.92	< 0.0001***	0.0001***
IGFBP-5	1595	1755	159	1.10	0.006**	0.0003***
GHBP	1619	1608	−11.4	0.99	0.926	0.655
Insulin	288	325	37.2	1.13	0.355	0.198

^*P-value ≤0.05;

^**P-value ≤0.01;

^***P-value ≤0.001

Abbreviations: MMP12 = matrix metalloproteinase-12; MDC = macrophage derived cytokine; IL-22 BP = interleukin-22 binding protein; LY9 = T lymphocyte antigen Ly9; FGG = fibrinogen gamma chain; ANGPT2 = angiopoietin-2; LT a1/b2 = lymphotoxin a1/b2; IGFBP-2 = insulin-like growth factor binding protein-2; ITGA1 ITGB1 = Integrin A1 B1; MMP-3 = matrix metalloproteinase-3; IGFBP-5 = insulin-like growth factor binding protein-5; GHBP = growth hormone binding protein.